Pasithea Therapeutics (KTTA) Return on Capital Employed (2021 - 2024)
Pasithea Therapeutics (KTTA) has disclosed Return on Capital Employed for 4 consecutive years, with 0.92% as the latest value for Q3 2024.
- Quarterly Return on Capital Employed fell 46.0% to 0.92% in Q3 2024 from the year-ago period, while the trailing twelve-month figure was 0.92% through Sep 2024, down 46.0% year-over-year, with the annual reading at 0.48% for FY2023, 22.0% down from the prior year.
- Return on Capital Employed hit 0.92% in Q3 2024 for Pasithea Therapeutics, down from 0.91% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 0.12% in Q4 2021 to a low of 0.92% in Q3 2024.
- Historically, Return on Capital Employed has averaged 0.44% across 4 years, with a median of 0.36% in 2023.
- Biggest five-year swings in Return on Capital Employed: decreased -16bps in 2022 and later plummeted -51bps in 2024.
- Year by year, Return on Capital Employed stood at 0.12% in 2021, then crashed by -131bps to 0.28% in 2022, then tumbled by -119bps to 0.62% in 2023, then plummeted by -49bps to 0.92% in 2024.
- Business Quant data shows Return on Capital Employed for KTTA at 0.92% in Q3 2024, 0.91% in Q2 2024, and 0.77% in Q1 2024.